Clinical trials
Completed Phase 1/2 Melanoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
168 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 4 |
| 2002 | 8 |
| 2003 | 5 |
| 2004 | 6 |
| 2005 | 9 |
| 2006 | 8 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 7 |
| 2010 | 7 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 11 |
| 2015 | 11 |
| 2016 | 15 |
| 2017 | 10 |
| 2018 | 12 |
| 2019 | 3 |
| 2020 | 9 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 168 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| Merck Sharp & Dohme LLC | 6 |
| Radboud University Medical Center | 6 |
| Craig L Slingluff, Jr | 5 |
| Novartis Pharmaceuticals | 5 |
| Incyte Biosciences International Sàrl | 4 |
| Inge Marie Svane | 4 |
| M.D. Anderson Cancer Center | 4 |
| Baylor Research Institute | 3 |
| Fred Hutchinson Cancer Center | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Melanoma | 168 |
| Carcinoma, Non-Small-Cell Lung | 25 |
| Neoplasm Metastasis | 21 |
| Neoplasms | 19 |
| Carcinoma, Renal Cell | 15 |
| Ovarian Neoplasms | 15 |
| Breast Neoplasms | 14 |
| Colorectal Neoplasms | 11 |
| Sarcoma | 11 |
| Lung Neoplasms | 10 |
Trials
Showing 1 to 25 of 168. Each trial links to its page on Pharma Observatory.
68 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.